MEDI-1191
- Generic Name
- MEDI-1191
Batiraxcept Fails to Meet Primary Endpoint in Phase III Ovarian Cancer Trial
• Aravive's batiraxcept demonstrated no significant difference in median progression-free survival compared to paclitaxel in platinum-resistant recurrent ovarian cancer patients.
• The Phase III trial termination led to a significant drop in batiraxcept's Likelihood of Approval (LoA) for ovarian cancer, decreasing by 10 points to 1%.
• The study found no detriment to overall survival and identified no new safety signals, despite the failure to meet the primary endpoint.
• The trial compared batiraxcept in combination with paclitaxel versus placebo in combination with paclitaxel.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath